Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Celcuity, Inc. (CELC : NSDQ)
 
 • Company Description   
Celcuity Inc. is a cellular analysis company. It engaged in discovering new cancer sub-types and commercializing diagnostic tests designed to significantly improve the clinical outcomes of cancer patients treated with targeted therapies. The company's proprietary CELx diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular activity driving a patient's cancer and the targeted therapy. Celcuity Inc. is based in Minneapolis, United States.

Number of Employees: 30

 
 • Price / Volume Information   
Yesterday's Closing Price: $13.01 Daily Weekly Monthly
20 Day Moving Average: 27,242 shares
Shares Outstanding: 14.91 (millions)
Market Capitalization: $194.03 (millions)
Beta: 1.53
52 Week High: $33.01
52 Week Low: $8.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -30.98% -28.83%
12 Week -40.24% -40.83%
Year To Date 42.03% 29.36%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
16305 36TH AVENUE NORTH SUITE 100
-
MINNEAPOLIS,MN 55446
USA
ph: 763-392-0767
fax: -
None http://www.celcuity.com
 
 • General Corporate Information   
Officers
Brian F. Sullivan - Chief Executive Officer and Chairman
Vicky Hahne - Chief Financial Officer
Lance G. Laing - Chief Science Officer; Vice President and Secretar
Richard E. Buller - Director
Dave F. Dalvey - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 15102K100
SIC: 8071
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/15/22
Share - Related Items
Shares Outstanding: 14.91
Most Recent Split Date: (:1)
Beta: 1.53
Market Capitalization: $194.03 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.77 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/15/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 2.61
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -70.83%
vs. Previous Quarter: 63.06%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -68.48
06/30/21 - -99.69
03/31/21 - -52.39
ROA
09/30/21 - -55.23
06/30/21 - -81.65
03/31/21 - -49.51
Current Ratio
09/30/21 - 32.30
06/30/21 - 27.51
03/31/21 - 30.50
Quick Ratio
09/30/21 - 32.30
06/30/21 - 27.51
03/31/21 - 30.50
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 4.99
06/30/21 - 2.14
03/31/21 - 2.86
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.19
06/30/21 - 0.53
03/31/21 - 0.00
Debt-to-Capital
09/30/21 - 16.23
06/30/21 - 34.50
03/31/21 - 0.02
 

Powered by Zacks Investment Research ©